tradingkey.logo
tradingkey.logo

Neogenomics Inc

NEO
View Detailed Chart
7.190USD
-0.570-7.35%
Close 03/27, 16:00ETQuotes delayed by 15 min
322.48MMarket Cap
LossP/E TTM

Neogenomics Inc

7.190
-0.570-7.35%
Intraday
1m
30m
1h
D
W
M
D

Today

-7.35%

5 Days

-9.67%

1 Month

-26.86%

6 Months

-7.46%

Year to Date

-38.86%

1 Year

-25.26%

View Detailed Chart

TradingKey Stock Score of Neogenomics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Neogenomics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 27 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.94.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neogenomics Inc's Score

Industry at a Glance

Industry Ranking
27 / 75
Overall Ranking
148 / 4542
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Neogenomics Inc Highlights

StrengthsRisks
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.93% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 727.33M.
Overvalued
The company’s latest PE is -8.53, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 134.55M shares, decreasing 5.86% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 156.64K shares of this stock.

Analyst Rating

Based on 14 analysts
Buy
Current Rating
13.944
Target Price
+79.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neogenomics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Neogenomics Inc Info

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Ticker SymbolNEO
CompanyNeogenomics Inc
CEOZook (Antony P)
Websitehttps://neogenomics.com/
KeyAI